Corona Remedies Q2 FY27 revenue up 22.2% to INR 441.2 Cr; H1 PAT up 22.2% to INR 120.4 Cr
Q2 FY27 revenue up 22.2% to INR 441.2 Cr, EBITDA up 22.3%; H1 FY27 PAT up 22.2% to INR 120.4 Cr.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue from Operations
- INR 441.2 Cr, up 22.2%
- Q2 FY27 EBITDA
- INR 96.0 Cr, up 22.3% at a 21.7% margin
- H1 FY27 PAT
- INR 120.4 Cr, up 22.2%
- Period
- Q2 & H1 FY27
- Positioning
- An India-focused pharmaceutical company, with India contributing 97.1% of H1 FY27 revenue, chronic and sub-chronic therapies ~72.1%, ranked 26th in the IPM as of MAT Sep-26.
🏭 Q2 FY27 revenue from operations rose 22.2% to INR 441.2 Cr and EBITDA rose 22.3% to INR 96.0 Cr at a 21.7% margin. PAT grew 15.3% to INR 60.3 Cr, with margin slipping to 13.7% from 14.5%, which the company attributes to higher depreciation and amortisation from new facilities and acquired brands.
💰 For H1 FY27, revenue was INR 863.6 Cr (+22.0%), EBITDA INR 189.1 Cr (+27.5%) and PAT INR 120.4 Cr (+22.2%), with annualised ROCE of 49.8% and ROE of 32.9%. FY26 revenue was 1,403.2 Cr and adjusted PAT 199.4 Cr.
🏭 The company describes itself as India-focused, with 97.1% of H1 revenue from India, a shift from a 70:30 to 28:72 acute:chronic mix between FY13 and FY26, and a climb to 26th rank in the IPM. It cites EU-GMP renewal, a new EU-GMP hormone facility at Bhayla and ANVISA Brazil certification in 2026.
🔬 Management lists five growth strategies: raise domestic market share through MR productivity, enter therapies such as nephrology, CNS, rheumatology, dermatology and gastroenterology, launch new products, pursue acquisitions and in-licensing, and use its hormone portfolio to enter regulated overseas markets.
Also from Corona Remedies
Corona Remedies Ltd press release, Q2 FY27
30 Oct 2026
Board approves unaudited Q2 and H1 results; auditors' review conclusion not modified
30 Oct 2026
Corona Remedies Ltd press release
22 Oct 2026
More numbers
- Revenue from operations, Q2 FY27INR 441.2 Cr
- Revenue growth Y-o-Y, Q2 FY2722.2%
- EBITDA, Q2 FY27INR 96.0 Cr
- PAT, Q2 FY27INR 60.3 Cr
- Revenue from operations, H1 FY27INR 863.6 Cr
- EBITDA, H1 FY27INR 189.1 Cr
- PAT, H1 FY27INR 120.4 Cr
- ROCE annualised, H1 FY2749.8%
- ROE annualised, H1 FY2732.9%
- Revenue from operations, FY261,403.2 (₹ Crores)
- Adjusted PAT, FY26199.4 (₹ Crores)
- Total equity, Mar-26746.9 (₹ Crores)
- Current borrowings, Mar-26142.9 (₹ Crores)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.